MARKET

JANX

JANX

Janux Therapeutics, Inc.
NASDAQ
15.33
+0.39
+2.58%
After Hours: 15.32 -0.01 -0.03% 17:29 06/29 EDT
OPEN
15.02
PREV CLOSE
14.94
HIGH
15.35
LOW
14.64
VOLUME
1.19M
TURNOVER
--
52 WEEK HIGH
35.34
52 WEEK LOW
12.12
MARKET CAP
934.59M
P/E (TTM)
-8.3211
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at JANX last week (0622-0626)?
Weekly Report · 18h ago
Janux Therapeutics Coverage Assumed by Truist Securities at Buy
Dow Jones · 4d ago
Janux Therapeutics Price Target Cut to $26.00/Share From $80.00 by Truist Securities
Dow Jones · 4d ago
Truist Securities Assumes Janux Therapeutics at Buy, Lowers Price Target of $26
Benzinga · 4d ago
Analysts Offer Insights on Healthcare Companies: Sionna Therapeutics, Inc. (SION) and Janux Therapeutics Inc (JANX)
TipRanks · 4d ago
Janux Therapeutics assumed with a Buy at Truist
TipRanks · 4d ago
JANUX THERAPEUTICS INC <JANX.O>: TRUIST SECURITIES ASSUMES COVERAGE WITH BUY RATING; TARGET PRICE $26 VS $80
Reuters · 4d ago
U.S. RESEARCH ROUNDUP-Caseys General Stores, Micron Technology, SAP
Reuters · 4d ago
More
About JANX
Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. It has developed three bispecific platforms: Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM). Its TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain. Its TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. Its clinical candidates include JANX007 and JANX008. JANX007 is a prostate-specific membrane antigen (PSMA-TRACTr) designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors. JANX008 is an epidermal growth factor receptor (EGFR-TRACTr), being studied for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and others.

Webull offers Janux Therapeutics Inc stock information, including NASDAQ: JANX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JANX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading JANX stock methods without spending real money on the virtual paper trading platform.